Literature DB >> 22129984

Crizotinib.

Alice T Shaw, Uma Yasothan, Peter Kirkpatrick.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22129984     DOI： 10.1038/nrd3600

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  8 in total

1.  Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.

Authors:  Alice T Shaw; Beow Y Yeap; Benjamin J Solomon; Gregory J Riely; Justin Gainor; Jeffrey A Engelman; Geoffrey I Shapiro; Daniel B Costa; Sai-Hong I Ou; Mohit Butaney; Ravi Salgia; Robert G Maki; Marileila Varella-Garcia; Robert C Doebele; Yung-Jue Bang; Kimary Kulig; Paulina Selaru; Yiyun Tang; Keith D Wilner; Eunice L Kwak; Jeffrey W Clark; A John Iafrate; D Ross Camidge
Journal:  Lancet Oncol       Date:  2011-09-18       Impact factor: 41.316

Review 2.  Targeted therapy in non-small-cell lung cancer--is it becoming a reality?

Authors:  Filip Janku; David J Stewart; Razelle Kurzrock
Journal:  Nat Rev Clin Oncol       Date:  2010-06-15       Impact factor: 66.675

3.  Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

Authors:  Eunice L Kwak; Yung-Jue Bang; D Ross Camidge; Alice T Shaw; Benjamin Solomon; Robert G Maki; Sai-Hong I Ou; Bruce J Dezube; Pasi A Jänne; Daniel B Costa; Marileila Varella-Garcia; Woo-Ho Kim; Thomas J Lynch; Panos Fidias; Hannah Stubbs; Jeffrey A Engelman; Lecia V Sequist; WeiWei Tan; Leena Gandhi; Mari Mino-Kenudson; Greg C Wei; S Martin Shreeve; Mark J Ratain; Jeffrey Settleman; James G Christensen; Daniel A Haber; Keith Wilner; Ravi Salgia; Geoffrey I Shapiro; Jeffrey W Clark; A John Iafrate
Journal:  N Engl J Med       Date:  2010-10-28       Impact factor: 91.245

4.  EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.

Authors:  Young Lim Choi; Manabu Soda; Yoshihiro Yamashita; Toshihide Ueno; Junpei Takashima; Takahiro Nakajima; Yasushi Yatabe; Kengo Takeuchi; Toru Hamada; Hidenori Haruta; Yuichi Ishikawa; Hideki Kimura; Tetsuya Mitsudomi; Yoshiro Tanio; Hiroyuki Mano
Journal:  N Engl J Med       Date:  2010-10-28       Impact factor: 91.245

5.  Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK).

Authors:  J Jean Cui; Michelle Tran-Dubé; Hong Shen; Mitchell Nambu; Pei-Pei Kung; Mason Pairish; Lei Jia; Jerry Meng; Lee Funk; Iriny Botrous; Michele McTigue; Neil Grodsky; Kevin Ryan; Ellen Padrique; Gordon Alton; Sergei Timofeevski; Shinji Yamazaki; Qiuhua Li; Helen Zou; James Christensen; Barbara Mroczkowski; Steve Bender; Robert S Kania; Martin P Edwards
Journal:  J Med Chem       Date:  2011-08-18       Impact factor: 7.446

6.  Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors.

Authors:  Ultan McDermott; A John Iafrate; Nathanael S Gray; Toshi Shioda; Marie Classon; Shyamala Maheswaran; Wenjun Zhou; Hwan Geun Choi; Shannon L Smith; Lori Dowell; Lindsey E Ulkus; Georgiana Kuhlmann; Patricia Greninger; James G Christensen; Daniel A Haber; Jeffrey Settleman
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

7.  An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms.

Authors:  Helen Y Zou; Qiuhua Li; Joseph H Lee; Maria E Arango; Scott R McDonnell; Shinji Yamazaki; Tatiana B Koudriakova; Gordon Alton; Jingrong J Cui; Pei-Pei Kung; Mitchell D Nambu; Gerrit Los; Steven L Bender; Barbara Mroczkowski; James G Christensen
Journal:  Cancer Res       Date:  2007-05-01       Impact factor: 12.701

8.  Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.

Authors:  Manabu Soda; Young Lim Choi; Munehiro Enomoto; Shuji Takada; Yoshihiro Yamashita; Shunpei Ishikawa; Shin-ichiro Fujiwara; Hideki Watanabe; Kentaro Kurashina; Hisashi Hatanaka; Masashi Bando; Shoji Ohno; Yuichi Ishikawa; Hiroyuki Aburatani; Toshiro Niki; Yasunori Sohara; Yukihiko Sugiyama; Hiroyuki Mano
Journal:  Nature       Date:  2007-07-11       Impact factor: 49.962
  8 in total
  35 in total

Review 1.  Ten things you should know about protein kinases: IUPHAR Review 14.

Authors:  Doriano Fabbro; Sandra W Cowan-Jacob; Henrik Moebitz
Journal:  Br J Pharmacol       Date:  2015-03-24       Impact factor: 8.739

2.  Immunology: Mind the immuno-connection gap.

Authors:  Wolfgang Link
Journal:  Nat Chem Biol       Date:  2017-04-24       Impact factor: 15.040

Review 3.  Omics and therapy - a basis for precision medicine.

Authors:  Joseph P Garay; Joe W Gray
Journal:  Mol Oncol       Date:  2012-03-08       Impact factor: 6.603

4.  Cancer genes in lung cancer: racial disparities: are there any?

Authors:  Ahmed El-Telbany; Patrick C Ma
Journal:  Genes Cancer       Date:  2012-07

5.  The discovery of medicines for rare diseases.

Authors:  David C Swinney; Shuangluo Xia
Journal:  Future Med Chem       Date:  2014-06       Impact factor: 3.808

6.  A novel lead compound CM-118: antitumor activity and new insight into the molecular mechanism and combination therapy strategy in c-Met- and ALK-dependent cancers.

Authors:  Lanfang Meng; Mengjun Shu; Yaqing Chen; Dexiao Yang; Qun He; Hui Zhao; Zhiyong Feng; Chris Liang; Ker Yu
Journal:  Cancer Biol Ther       Date:  2014-03-11       Impact factor: 4.742

7.  miR-4326 promotes lung cancer cell proliferation through targeting tumor suppressor APC2.

Authors:  Guopeng Xu; Zhongwei Zhang; Li Zhang; Ying Chen; Ning Li; Yantian Lv; Yong Li; Xiao Xu
Journal:  Mol Cell Biochem       Date:  2017-11-03       Impact factor: 3.396

8.  Synthesis of a [(18)F]-labeled ceritinib analogue for positron emission tomography of anaplastic lymphoma kinase, a receptor tyrosine kinase, in lung cancer.

Authors:  Sandun Perera; David Piwnica-Worms; Mian M Alauddin
Journal:  J Labelled Comp Radiopharm       Date:  2016-02-08       Impact factor: 1.921

9.  Crizotinib-loaded polymeric nanoparticles in lung cancer chemotherapy.

Authors:  Zhi-Ming Jiang; Shou-Ping Dai; Yong-Qing Xu; Tao Li; Jian Xie; Chong Li; Zhong-Hui Zhang
Journal:  Med Oncol       Date:  2015-05-30       Impact factor: 3.064

Review 10.  Regulation of Bim in Health and Disease.

Authors:  Ronit Vogt Sionov; Spiros A Vlahopoulos; Zvi Granot
Journal:  Oncotarget       Date:  2015-09-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.